Renovaro BioSciences Inc. RENB Archives - Page 2 of 3

FridayOct 20, 2023 2:28 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, will be spotlighted in webinar taking place today. The webinar is scheduled to start at 3 p.m. ET. Renovaro BioSciences CEO Mark Dybul will be featured in the webinar, which is titled “Future Health Tech: Challenges and Opportunities,” and will provide key information about the company and its role as a leader in the health tech space. Those interested in joining the webinar can call in by dialing 1-507-473-4847 in the United States, then use…

WednesdayOct 11, 2023 1:41 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Appoints Intel Capital Cofounder to Board

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company's strategy and business development efforts. Miller’s impressive decades-long career includes strategic and responsible roles in both the technology and medical industries. After spending 13 years in the medical science space, he moved to high tech where, in addition to cofounding Intel Capital, he served as the company’s corporate vice president of…

TuesdayOct 10, 2023 2:28 pm

QualityStocksNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Strategic Board Appointments of Two Finance Industry Experts

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, today announced the appointment of Leni Boeren and Ruud Hendriks as independent directors. Both Boeren and Hendriks bring extensive, high-level experience in finance and business. Boeren has a 40-year career in the financial sector, commencing with banking roles at Paribas and Rabobank before holding several director-level positions at Amsterdam exchanges and then Euronext. Hendriks brings more than 35 years of experience in the asset management industry, having held senior roles at some of the most established financial institutions.…

MondayOct 02, 2023 2:00 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Releases Shareholder Letter Regarding Agreement to Combine with Leading AI Company

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a shareholder letter from Renovaro CEO Mark R. Dybul, MD. In the letter, Dybul provides information about the definitive agreement the company recently signed with artificial intelligence company GEDiCube. In the letter, Dybul noted that the two companies decided to combine in order to accelerate a shared mission to transform medicine and promote healthy longevity through the synergistic applications of advanced AI technology and pioneering biotherapeutics. Dybul noted that he anticipates serving as…

FridaySep 29, 2023 1:59 pm

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company would focus on accelerating precision and personalized medicine for longevity powered by mutually reinforcing artificial intelligence (“AI”) and biotechnology platforms to enable early diagnosis, better targeted treatments and drug discovery. GEDi Cube is an artificial intelligence medical technology company. According…

WednesdaySep 20, 2023 11:15 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers GEDI Cube is strengthening its platform’s potential by joining with the NVIDIA Inception program, which nurtures start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists The companies hope to detect pancreatic tumors at early…

FridaySep 15, 2023 1:01 pm

QualityStocksNewsBreaks – Why Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

Renovaro BioSciences (NASDAQ: RENB), (formerly Enochian BioSciences Inc.), is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy. “Renovaro aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, as well as to potentially treat or cure serious infectious diseases… The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human phase I/IIa studies that are on track to start by mid-2024,” reads a recent article. “Renovaro’s proprietary, novel…

WednesdayAug 30, 2023 11:03 am

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting the body’s natural tumor-fighting mechanisms with artificial intelligence and machine learning technology. “This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” said GEDiCube…

FridayAug 25, 2023 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Aims to Unlock Potential Treatments and Cures for Serious Infectious Diseases and Cancer

Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results As an advanced, pre-clinical biotechnology company specializing in cell, gene, and immunotherapy, Renovaro BioSciences (NASDAQ: RENB), formerly Enochian BioSciences Inc., aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers and to…

WednesdayAug 23, 2023 1:12 pm

QualityStocksNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. “We are grateful to the FDA for the very timely, thorough and clear direction that was provided. After a comprehensive review by our management, scientific, regulatory, and clinical operations teams, we believe we have a clear path…

Site Search

Company Search

Tag: Renovaro BioSciences Inc. RENB